|
|
|
03 Sep 2008 |
Phase III U.S. Pivotal Study Results on CSL Biotherapies' Afluria Published in Vaccine
|
|
02 Sep 2008 |
InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
|
|
02 Sep 2008 |
Optimer Pharmaceuticals Completes Enrollment in Second Prulifloxacin Phase 3 Clinical Trial
|
|
31 Aug 2008 |
Novartis decides not to pursue further development of Aurograb(TM)
|
|
31 Aug 2008 |
INTELENCE(TM) (Etravirine) Receives Marketing Authorisation in the European Union for HIV Combination Therapy
|
|
28 Aug 2008 |
Intercell announces initiation of further Phase II clinical trial of V710 an investigational vaccine
|
|
27 Aug 2008 |
Nexmed Announces Decision for NM100060
|
|
26 Aug 2008 |
Novavax Announces Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program
|
|
25 Aug 2008 |
Genzyme Corporation and Medicines for Malaria Venture Announce New Collaboration with Advinus Therapeutics to Accelerate Discovery of Novel Therapies for Malaria
|
|
24 Aug 2008 |
Influenza Antibody Spray Success: Opens New Approach to Respiratory Disease Control
|
|
24 Aug 2008 |
Indevus Pharmaceuticals Announces Completion of Enrollment in Phase III Trial of PRO 2000
|
|
21 Aug 2008 |
FDA Requires Additional Information on DORIBAX for Treatment of Hospital-Acquired Pneumonia
|
|
21 Aug 2008 |
Arpida's Iclaprim MAA accepted for review by EMEA
|
|
21 Aug 2008 |
VaxInnate's M2e Universal Influenza Vaccine Candidate Demonstrates Safety and Immunogenicity in Phase I Clinical Study
|
|
21 Aug 2008 |
VaxInnate's M2e Universal Influenza Vaccine Candidate Demonstrates Safety and Immunogenicity in Phase I Clinical Study
|
|
21 Aug 2008 |
PolyMedix Initiates Dosing in Phase I Clinical Study of Novel Systemic Antibiotic Compound
|
|
20 Aug 2008 |
BioVex Announces Regulatory Clearance to Commence a Clinical Study With ImmunoVEX HSV2; A Vaccine Candidate for Genital Herpes
|
|
20 Aug 2008 |
DelSite Files IND for Nasal Powder H5N1 (Bird Flu) Influenza Vaccine
|
|
19 Aug 2008 |
Vertex Pharmaceuticals to Start Phase 3 'REALIZE' Trial with Telaprevir in Treatment-Failure HCV Patients
|
|
19 Aug 2008 |
EndoBiologics, Incorporated, and PATH Form New Collaboration to Research Vaccine Candidates Against Diarrheal Disease
|
|
13 Aug 2008 |
MDRNA, Inc. Lead Candidate Demonstrates In Vivo Efficacy against Seasonal and Pandemic Flu Strains
|
|
12 Aug 2008 |
U.S. Food and Drug Administration Approves Viread(R) for Chronic Hepatitis B in Adults
|
|
11 Aug 2008 |
Human rhinovirus Phase IIa clinical trial commences
|
|
10 Aug 2008 |
Ardea Biosciences Presents Phase 2a Antiviral Activity Data for Lead HIV Candidate, RDEA806 at XVII International AIDS Conference
|
|
10 Aug 2008 |
Trimeris Reports Financial Results for the Second Quarter 2008 and Top-Line Results from Its Phase 1 Clinical Study of TRI-1144
|
|
07 Aug 2008 |
DOR BioPharma Announces Initiation of Second Human Clinical Trial for RiVax(TM), Its Ricin Toxin Vaccine
|
|
06 Aug 2008 |
Ninety-Six Week Data on Tibotec Investigational NNRTI, TMC278, Presented at AIDS 2008
|
|
06 Aug 2008 |
FDA Approves Expanded Label for CANCIDAS® (caspofungin acetate) as the First and Only Echinocandin Therapy for the Treatment of Pediatric Patients (3 months and older) with Indicated Fungal Infections
|
|
05 Aug 2008 |
Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
|
|
05 Aug 2008 |
CASTLE Data Showed Boosted REYATAZ(R) (atazanavir sulfate) and Lopinavir/r Achieved Similar Results for Undetectable Viral Load in Treatment-Naive HIV-1 Infected Patients, Regardless of Gender
|
|
05 Aug 2008 |
ISENTRESS(R) (raltegravir), Merck's First in Class Integrase Inhibitor, Reduced HIV Viral Load and Increased CD4 Cell Counts Through 96 Weeks in Treatment-Naïve HIV-Infected Patients When Taken With Other Anti-HIV Medicines
|
|
05 Aug 2008 |
Bionor Immuno have started a Vacc-4x Phase IIB TOC study in US and Europe with enrollment of 345 patients.
|
|
05 Aug 2008 |
Argos Therapeutics´ Arcelis™ Personalized Immunotherapy Platform in HIV Achieves Primary Endpoint in Phase 1 Trial
|
|
05 Aug 2008 |
Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial
|
|
04 Aug 2008 |
Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients
|
|
04 Aug 2008 |
New data shows HIV therapy tipranavir (Aptivus(R)) is effective and well tolerated in children
|
|
31 Jul 2008 |
LANI Phase II completed - Phase III scheduled
|
|
29 Jul 2008 |
Idenix Pharmaceuticals Advances HCV Discovery Program to Clinic
|
|
28 Jul 2008 |
OctoPlus proves efficacy of OP-145 in Phase II ear infection study
|
|
28 Jul 2008 |
Arpida submits Marketing Authorisation Application for intravenous iclaprim in Europe
|
|
28 Jul 2008 |
Ambrilia Provides Update on PPL-100 Partnership With Merck & Co, Inc.
|
|
28 Jul 2008 |
BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting
|
|
28 Jul 2008 |
BioDelivery Sciences Initiates Bioral(R) Amphotericin B Clinical Program
|
|
24 Jul 2008 |
MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis
|
|
23 Jul 2008 |
Gilead Initiates Phase III Clinical Trial of Elvitegravir, an Investigational Integrase Inhibitor for HIV
|
|
23 Jul 2008 |
Optimer Pharmaceuticals Completes Enrollment in OPT-80 Phase 3 Clinical Trial in Patients with Clostridium difficile Infection
|
|
23 Jul 2008 |
Depomed's ProQuin(R) XR Achieves First Marketing Authorization in Europe
|
|
17 Jul 2008 |
FDA Advisory Committee Provides Opinion of DORIBAX(TM) for the Treatment of Hospital-Acquired Pneumonia
|
|
17 Jul 2008 |
Optimer Pharmaceuticals Announces Positive Results in Prulifloxacin Phase 3 Study
|
|
17 Jul 2008 |
Sciele Pharma Announces That the FDA Has Issued an Approvable Letter for the Head Lice Treatment
|
| |
|
Results 101 - 150 of 1267 |
